Many clinicians ask us: What is the difference between Class 3 and Class 4 Lasers? There is a slew of false information in the public domain, perpetuated mainly by the manufacturers of these devices, regarding the effectiveness and cellular mechanisms activated during class 4 laser light irradiation. Many class 4 laser manufacturers are intentionally or unintentionally misleading healthcare practitioners into believing that higher power and longer NIR wavelengths equate to deeper tissue penetration and better clinical efficacy. Nothing could be further from the truth. The truth is… Unfortunately, all of these claims turn out to be fancy sales gimmicks, as they have not the standing in the clinical or scientific journals to support their claims. The clinical and scientific facts are clear that because of the very high absorption of NIR laser light by water at wavelengths greater than 950 nm, 99% of the energy produced at this wavelength or … Read More
What is Cold Laser Therapy?
History Cold Laser Therapy (“CLT”) or treatment with light has been in existence since 1500 BC; where, Indian medical literature described a treatment combining herbs with natural sunlight to treat non-pigmented skin areas, known today as vitiligo. Buddhist literature from 200 AD and 10th century Chinese documents make similar references.1 As an analogy, just like the abacus eventually evolved into the computer, which has fundamentally changed the way humans live and work in today’s society (put up your hand if you can go a day without your smartphone), light therapy, using research from 3500 years ago, has evolved into CLT systems capable of delivering laser light at specific wavelengths (colours) and power levels to heal numerous nerve, muscle and joint conditions. Benefits As advancements in CLT technology have continued, millions of healthcare practitioners now rely on CLT systems daily in their clinics to treat a wide variety of conditions by: … Read More
Developing a Potential Cure for Bladder Cancer
Current bladder cancer treatments are not curative. A novel photodynamic therapy (PDT) platform being developed by Theralase could be the new gold standard. Limited Options for Bladder Cancer Patients Bladder cancer is the ninth most common cancer globally.1 Approximately 75–85% of patients with bladder cancer present with non-muscle invasive bladder cancer (NMIBC). Adjuvant intravesical instillations with bacillus Calmette-Guérin (BCG) is the recommended treatment option for patients with intermediate- and high-risk NMIBC. Despite adequate BCG treatment, a large proportion of patients experience a recurrence. Although radical cystectomy is the gold standard for BCG-unresponsive NMIBC, some patients are unfit or unwilling to consider this option. BCG also has known side effects that impact patient acceptance and there has been a worldwide supply shortage since 2012. Despite bladder cancer being the fifth most common cancer in the United States, there have been virtually no advances in its treatment. Currently, intravesical therapies are limited by … Read More
Theralase Releases Quarterly Newsletter
Toronto, Ontario – Jan 07, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, today is pleased to release the Company Quarterly Newsletter. The Newsletter provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study. The Newsletter can be found on the Company’s website www.theralase.com/invest/. To receive future Newsletters, please contact info@theralase.com. About Theralase® Technologies Inc. Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. Additional information is available at www.theralase.com and www.sedar.com Forward-Looking Information This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and … Read More
Theralase Releases Third Quarter 2019 Financial Results and Company Update
TORONTO, ON/ November 29, 2019 / Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs“) and their associated drug formulations intended to safely and effectively destroy various cancers, today released financial results for the nine-month period ended September 30, 2019. Financial Highlights: Condensed Consolidated Statements of Operations (Unaudited) Three-Month Ended Sep 30 Nine-Month Ended Sep 30 In Canadian Dollars 2019 2018 2019 2018 Total Revenues $144,455 $365,940 $514,891 $1,276,630 Cost of sales $106,396 $126,975 $374,040 $559,296 Gross margin $38,059 $238,965 $140,851 $717,334 As percentage of revenue 26% 65% 27% 56% Net loss ($1,786,777) ($722,817) ($4,399,045) ($2,612,168) Loss per share ($0.01) ($0.006) ($0.03) ($0.02) Total revenue for the nine-month period ended September 30, 2019 decreased to $514,891 from $1,276,630 for the same period in 2018, a 60% decrease. In Canada, revenue decreased 44% to $477,502 from … Read More
Theralase Researchers Receive Recognition for Recent Scientific Publications
Toronto, Ontario – November 27, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce several scientific recognitions. The recognition from three scientific institutes emphasizes the strong science-based technology that the Company possesses, verifying that Theralase’s Ruthenium-based PDCs are leading the pack in terms of performance of Photo Dynamic Therapy (“PDT”) metal based PDCs to become the next viable option for treating various cancers, suggesting a major change in the way various cancers are treated in the future. The review article, titled “Metal-Based photosensitizers for photodynamic therapy – the future of multimodal oncology?”, is available online at www.sciencedirect.com and will be published in a special issue of Current Opinion in Chemical Biology entitled Next … Read More
Theralase Announces Leadership Transition
Toronto, Ontario – October 31, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today the departure of its Chief Executive Officer – Device Division, Kipton Lade from the Company. Effective immediately, Shawn Shirazi, Ph.D., Chief Executive Officer – Drug Division, has agreed to become the sole CEO of the Company and will work with the Board to begin a search to identify a new leader to guide the Device Division in its next phase of growth. “We thank Kipton for his contributions to the Company over the last 8 months and we wish him well,” said Theralase Technologies Chairman of the Board of Directors, Guy Anderson. “We are also excited with the prospects of the TLD-1433 Anti-Cancer Technology (“ACT”) platform as it has the potential … Read More
Theralase – Participating in Bladder Cancer Walk 2019
Theralase® is proud to support the Bladder Cancer Canada annual awareness walk. Bladder Cancer Canada is the first and only Canadian patient advocacy organization dedicated to bladder cancer issues. Bladder cancer is the fifth most common cancer worldwide and approximately 241,000 new cases of bladder cancer will be diagnosed in Canada, the United States and Europe this year 1. Theralase’s lead cancer indication, currently being evaluated in a Phase II clinical study is Bacillus Calmete Guérin (“BCG”)-Unresponsive Carcinoma In-Situ (“CIS”) Non-Muscle Invasive Bladder Cancer (“NMIBC”). These PhotoDynamic Compounds (“PDC”) are able to hunt and penetrate preferentially into cancer cells, leaving healthy cells intact, and when laser light activated destroy the cancer cells safely and effectively with minimum to no side effects. If this pivotal study is proven successful, it will lead to a safe and effective treatment option for patients presenting with devastating disease. When a patient hears the word … Read More
Canadian Clinical Stage Biopharmaceutical Company Advances New Cancer Treatment
A Toronto based clinical-stage biopharmaceutical company is quickly advancing on what may prove to be one of the safest and most effective cancer treatments ever developed. Theralase Technologies Inc. (“Theralase”) is conducting a pivotal Phase II clinical study, with a primary objective of efficacy, of a cutting-edge anti-cancer treatment that utilizes laser light activated anti-cancer drugs; known as Photo Dynamic Compounds (“PDCs”), to destroy cancer cells from the inside out. In other words, these PDCs are able to penetrate preferentially into cancer cells, leaving healthy cells intact, and when laser light activated destroy the cancer cells safely and effectively with minimum to no side effects. Theralase is currently investigating these PDCs in the destruction of Non-Muscle Invasive Bladder Cancer (“NMIBC”) via a pivotal Phase II clinical study. Founded in 1994,Theralase commenced the research, development and commercialization of therapeutic lasers for the elimination of knee pain and continues this business today; … Read More
Theralase Granted European Patent for Anti-Cancer Photo Dynamic Compounds
Toronto, Ontario – October 22, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the Company has been granted a European Patent for their anti-cancer PDCs, which will issue in due course. The patent entitled, “Metal-Based Thiophene Photodynamic Compounds and Their Use” advances Theralase’s intellectual property portfolio internationally strengthening the patent portfolio around the Anti-Cancer Technology (“ACT”) platform. The patent encompasses an extensive library of PDCs, including Theralase’s lead PDC, TLD-1433, approved by Health Canada to be evaluated in a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”). Currently, Study II has successfully been launched in 3 Canadian clinical oncology sites with 2 patients treated. The Company has … Read More